Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers - A first-time-in-human single ascending dose study

Thrombosis Research

Volumn 127, Issue 4, 2011, Pages 292-298

  Rico, Salvador ^a,b   Antonijoan, Rosa Maria ^a,b   Gich, Ignasi ^a,b   Borrell, Montserrat ^a   Fontcuberta, Jordi ^a   Monreal, Mayte ^c   Martinez Gonzalez, Javier ^c   Barbanoj, Manel J ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

anti FXa; anticoagulants; pharmacodynamics; RO 14; safety; ultra low molecular weight heparin

Indexed keywords

ANTITHROMBIN; FIBRINOGEN; HEPARIN DERIVATIVE; RO 14; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MEDICAL EXAMINATION; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBIN TIME; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM; VOLUNTEER;

ADOLESCENT; ADULT; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79952992899     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.12.009     Document Type: Article

References (27)

1. B. Furie, and B.C. Furie Mechanisms of thrombus formation N Engl J Med 359 9 2008 Aug 28 938 949
2. J.I. Weitz Low-molecular-weight heparins N Engl J Med 337 10 1997 Sep 4 688 698 (Pubitemid 27375477)
3. E. Gray, B. Mulloy, and T.W. Barrowcliffe Heparin and low-molecular-weight heparin Thromb Haemost 99 5 2008 May 807 818 (Pubitemid 351705297)
4. J. Hirsh, and R. Raschke Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl 2004 Sep 188S 203S (Pubitemid 39297954)
5. C. Kearon, S.R. Kahn, G. Agnelli, S. Goldhaber, G.E. Raskob, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 Jun 454S 545S (Pubitemid 351892971)
6. A.D. Blann, and C.W. Khoo The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants Vasc Health Risk Manag 5 2009 693 704
7. J. Fareed, and J.M. Walenga Why differentiate low molecular weight heparins for venous thromboembolism? Thromb J 5 2007 8
8. E. Racine Differentiation of the low-molecular-weight heparins Pharmacotherapy 21 6 Pt 2 2001 Jun 62S 70S
9. J.F. van der Heijden, M.H. Prins, and H.R. Buller For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 100 2 2000 Oct 15 V121 V130
10. M.R. Lassen, O.E. Dahl, P. Mismetti, D. Destree, and A.G. Turpie AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: a dose-ranging study J Thromb Haemost 7 4 2009 Apr 566 572
11. S.S. Ahmad, F.S. London, and P.N. Walsh The assembly of the factor X-activating complex on activated human platelets J Thromb Haemost 1 1 2003 Jan 48 59
12. R.J. Leadley Jr. Coagulation factor Xa inhibition: biological background and rationale Curr Top Med Chem 1 2 2001 Jun 151 159
13. C. Viskov, M. Just, V. Laux, P. Mourier, and M. Lorenz Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026 J Thromb Haemost 7 7 2009 Jul 1143 1151
14. P. Carrasco, G. Franco, and M.T. Gomez Low Molecular Weight Heparins: Standardization and Biosimilars 3rd International Workshop on Characterisation of Heparin Products. Rockville, Maryland, July 27- 28, 2009 2010
15. WHO International Standard - 2nd International Standard for Low Molecular Weight Heparin. [NIBSC code: 01/608 Instructions for use (Version 2.0, Dated 01/04/2008)], United Kingdom. 2010. National Institute for Biological Standards and Control.
16. Guidance for Industry [cited 2008 Jun 10]; Available from: URL: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005 U S Food and Drug Administration http://www.fda.gov/cder/guidance/index.htm
17. Laboratorios Farmacéuticos Rovi SA. RO-14: Investigator's Brochure. 2009.
18. WHO-UMC [cited 2009 Dec 14];Available from: URL Causality Assessment of Adverse Events 2009 The Uppsala Monitoring Centre http://www.who-umc.org/ DynPage.aspx?id=22682
19. N.M. Milovic, J.R. Behr, M. Godin, C.S. Hou, K.R. Payer, and A. Chandrasekaran Monitoring of heparin and its low-molecular-weight analogs by silicon field effect Proc Natl Acad Sci USA 103 36 2006 Sep 5 13374 13379 (Pubitemid 44380115)
20. M.L. Larsen, U. Abildgaard, A.N. Teien, and K. Gjesdal Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238) Thromb Res 13 2 1978 Aug 285 288 (Pubitemid 9043347)
21. R.M. Antonijoan, S. Rico, J. Martinez-Gonzalez, M. Borrell, D. Valcarcel, and J. Fontcuberta Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers Int J Clin Pharmacol Ther 47 12 2009 Dec 726 732
22. Dubruc C, Karimi-Anderesi N, Lunven C, Zhang M, Grossmann M, Potgieter H. Pharmacokinetics of a New, Ultra-Low Molecular Weight Heparin, Semuloparin (AVE5026), in Healthy Subjects. Results From the First Phase I Studies. 51st American Society of Hematology Annual Meeting and Exposition. 12-3-0009. 1-26-0010.
23. L. Falkon, M. Gari, M. Barbanoj, J. Amiral, and J. Fontcuberta Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses Blood Coagul Fibrinolysis 9 2 1998 Mar 137 141 (Pubitemid 28216258)
24. J. Martinez-Gonzalez, L. Vila, and C. Rodriguez Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism Expert Rev Cardiovasc Ther 6 6 2008 Jul 793 802
25. Lovenox (Enoxaparin sodium) NDA 20-164 - Approval. CDER - U S Food and Drug Administration 1993 March 29Available from: URL: http://www.accessdata.fda. gov/drugsatfda-docs/nda/pre96/20-164-review.pdf
26. Fragmin (Dalteparin sodium) NDA 20-287 - Labeling revision approval. CDER - U S Food and Drug Administration 2004 April 21Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/020287-s034- FRAGMIN%20INJECTION.pdf
27. Innohep (Tinzaparin sodium) NDA 20-484 - Clinical Pharmacology and Biopharmaceutics Review. CDER - U S Food and Drug Administration 2000 July 14Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/ 20-484-Innohep-biopharmr-P1.pdf